Gemcitabine hydrochloride has been evaluated in numerous clinical trials spanning Phase 1 through Phase 4, with a primary emphasis on Phase 2 and Phase 3 studies. Sponsored by academic medical centers and biopharmaceutical enterprises, these studies feature diverse recruitment statuses—including recruiting, completed, and not yet recruiting—and evaluate gemcitabine as monotherapy and within multi-agent combination regimens across various malignancies, such as pancreatic cancer, non-small cell lung cancer, biliary tract cancer, advanced ovarian cancer, recurrent osteosarcoma, and nasopharyngeal carcinoma.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07528768 | NOT_YET_RECRUITING | Triple Negative Breast Cancer; Metastatic Triple-negative Breast Cancer |
AntiCancer Research Jamaica |
2026-06-01 | PHASE2 |
| NCT04198766 | RECRUITING | Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma; Resectable Non-Small-Cell Lung Cancer |
Inhibrx Biosciences, Inc |
2019-12-10 | PHASE1; PHASE2 |
| NCT06714604 | RECRUITING | Locally Advanced Pancreatic Adenocarcinoma; Borderline Resectable Pancreatic Carcinoma; Pancreas Cancer; Neoadjuvant Chemotherapy; Surgery; Pancreatectomy |
Sahlgrenska University Hospital |
2023-10-18 | PHASE3 |
| NCT05919537 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer; Pancreatic Cancer; Locally Advanced Solid Tumor; Metastatic Solid Tumor |
Hummingbird Bioscience |
2023-09-06 | PHASE1 |
| NCT06608927 | ACTIVE_NOT_RECRUITING | Metastatic Pancreatic Ductal Adenocarcinoma |
Arcus Biosciences, Inc. |
2024-12-13 | PHASE3 |
| NCT07184788 | NOT_YET_RECRUITING | Aggressive B-Cell Lymphoma |
Navy General Hospital, Beijing |
2025-10-01 | PHASE2 |
| NCT07001618 | RECRUITING | NSCLC (Advanced Non-small Cell Lung Cancer) |
Gustave Roussy, Cancer Campus, Grand Paris |
2025-11-17 | PHASE2 |
| NCT07155629 | NOT_YET_RECRUITING | Pancreatic Cancer Resectable |
Helsinki University Central Hospital |
2025-09-01 | PHASE3 |
| NCT05538663 | ACTIVE_NOT_RECRUITING | Non-muscle-invasive Bladder Cancer |
ECOG-ACRIN Cancer Research Group |
2023-02-07 | PHASE3 |
| NCT07365306 | RECRUITING | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent Primary Mediastinal Large B-Cell Lymphoma; Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified; Refractory Primary Mediastinal Large B-Cell Lymphoma; Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma |
City of Hope Medical Center |
2026-07-27 | PHASE2 |
| NCT04796220 | ACTIVE_NOT_RECRUITING | Breast Cancer; Breast Neoplasms |
Patrick Dillon, MD |
2022-01-27 | PHASE1 |
| NCT07683221 | NOT_YET_RECRUITING | Pancreatic Cancer |
Shandong Cancer Hospital and Institute |
2026-07-15 | PHASE2 |
| NCT07028424 | NOT_YET_RECRUITING | PDAC - Pancreatic Ductal Adenocarcinoma |
GERCOR - Multidisciplinary Oncology Cooperative Group |
2025-07 | PHASE2 |
| NCT07129993 | RECRUITING | Urothelial Cancer; Bladder Cancer |
Daiichi Sankyo |
2025-09-26 | PHASE2; PHASE3 |
| NCT07076121 | ACTIVE_NOT_RECRUITING | Pancreatic Ductal Adenocarcinoma |
Bristol-Myers Squibb |
2025-10-23 | PHASE2; PHASE3 |
| NCT06632327 | ACTIVE_NOT_RECRUITING | Resectable Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8 |
Alliance for Clinical Trials in Oncology |
2024-12-11 | PHASE3 |
| NCT05979961 | ACTIVE_NOT_RECRUITING | Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2023-09-07 | PHASE3 |
| NCT07578337 | NOT_YET_RECRUITING | Untreated; Advanced Pancreatic Cancer |
Nelum Corp |
2026-07-15 | PHASE2 |
| NCT07106762 | RECRUITING | Urothelial Cancer |
Bristol-Myers Squibb |
2025-09-30 | PHASE2; PHASE3 |
| NCT07277452 | NOT_YET_RECRUITING | Pancreatic Cancer, Adult |
The First Affiliated Hospital with Nanjing Medical University |
2025-12-10 | PHASE2 |
| NCT07226856 | RECRUITING | Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8 |
Mayo Clinic |
2025-12-12 | PHASE2 |
| NCT07036380 | RECRUITING | Advanced Biliary Tract Carcinoma |
Centre Hospitalier Universitaire de Besancon |
2025-12-22 | PHASE2 |
| NCT07213804 | RECRUITING | Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Neoplasm Metastasis |
Eli Lilly and Company |
2025-10-22 | PHASE3 |
| NCT07238283 | RECRUITING | First-line Treatment of Metastatic Pancreatic Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2025-12-02 | PHASE3 |
| NCT06904378 | RECRUITING | Metastatic Pancreatic Ductal Adenocarcinoma |
Washington University School of Medicine |
2026-03-25 | PHASE1; PHASE2 |
| NCT06561763 | NOT_YET_RECRUITING | High Risk Locally Advanced Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2024-08-20 | PHASE3 |
| NCT06204614 | ENROLLING_BY_INVITATION | Muscle Invasive Bladder Urothelial Carcinoma |
Brigham and Women's Hospital |
2024-06-14 | EARLY_PHASE1 |
| NCT07445295 | NOT_YET_RECRUITING | Metastatic Pancreatic Ductal Adenocarcinoma |
Chipscreen Biosciences, Ltd. |
2026-03-31 | PHASE3 |
| NCT04241276 | ACTIVE_NOT_RECRUITING | Pancreatic Cancer |
Queen Mary University of London |
2020-04-30 | PHASE2 |
| NCT06459180 | ACTIVE_NOT_RECRUITING | Cervical Cancer |
Merck Sharp & Dohme LLC |
2024-07-24 | PHASE3 |
| NCT07252375 | NOT_YET_RECRUITING | Nasopharyngeal Carcinoma (NPC); CTIT-Chemotherapy Induced Thrombocytopenia |
Fujian Cancer Hospital |
2025-11-30 | PHASE2 |
| NCT07685470 | NOT_YET_RECRUITING | Pancreatic Ductal Adenocarcinoma (PDAC); Second Line Treatment |
Peking Union Medical College Hospital |
2026-06-08 | PHASE1; PHASE2 |
| NCT07144254 | RECRUITING | Osteosarcoma Recurrent; Osteosarcoma in Children; Relapsed Osteosarcoma; Refractory Osteosarcoma |
Emory University |
2026-01-22 | PHASE1 |
| NCT06929286 | RECRUITING | Non-Muscle Invasive Bladder Cancer |
Memorial Sloan Kettering Cancer Center |
2025-04-11 | PHASE3 |
| NCT06926868 | RECRUITING | Breast Neoplasms |
Bristol-Myers Squibb |
2025-09-11 | PHASE2; PHASE3 |
| NCT06508658 | ACTIVE_NOT_RECRUITING | Diffuse Large B-Cell Lymphoma |
Genmab |
2024-08-13 | PHASE3 |
| NCT07480850 | ACTIVE_NOT_RECRUITING | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2026-01-01 | PHASE2 |
| NCT07598318 | NOT_YET_RECRUITING | Cholangiocarcinoma |
Sir Run Run Shaw Hospital |
2026-05-20 | PHASE2; PHASE3 |
| NCT06692491 | NOT_YET_RECRUITING | Rare Tumour |
Peking University Shenzhen Hospital |
2025-01-01 | PHASE2 |
| NCT07705919 | NOT_YET_RECRUITING | Borderline Resectable Pancreatic Ductal Adenocarcinoma |
Ohio State University Comprehensive Cancer Center |
2026-09-01 | PHASE1; PHASE2 |
| NCT05601440 | RECRUITING | Breast Cancer |
Canadian Cancer Trials Group |
2023-06-13 | PHASE2 |
| NCT06629597 | ACTIVE_NOT_RECRUITING | Nasopharyngeal Carcinoma |
MediLink Therapeutics (Suzhou) Co., Ltd. |
2024-12-31 | PHASE3 |
| NCT07229586 | RECRUITING | Solid Tumor |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
2025-12-02 | PHASE1; PHASE2 |
| NCT07451652 | RECRUITING | Relapsed/Refractory Diffuse Large B Cell Lymphoma |
Hospital Universitario Dr. Jose E. Gonzalez |
2026-03-17 | PHASE2 |
| NCT06483555 | RECRUITING | Pancreatic Adenocarcinoma; Metastatic Pancreatic Cancer; Basal Cell Neoplasm |
UNC Lineberger Comprehensive Cancer Center |
2025-02-06 | PHASE1; PHASE2 |
| NCT06962267 | RECRUITING | Pancreatic Cancer |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. |
2025-04-18 | PHASE2 |
| NCT06752811 | RECRUITING | Pancreatic Cancer Metastatic |
Shanghai Yizhong Pharmaceutical Co., Ltd. |
2025-02-05 | PHASE3 |
| NCT07030140 | RECRUITING | Cholangiocarcinoma; Hilar Cholangiocarcinoma; Bile Duct Cancer |
Jinbo Yue |
2025-07-01 | PHASE2 |
| NCT05096663 | ACTIVE_NOT_RECRUITING | Advanced Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 |
SWOG Cancer Research Network |
2022-03-15 | PHASE2; PHASE3 |
| NCT06502080 | NOT_YET_RECRUITING | Biliary Tract Cancer |
Shanghai Zhongshan Hospital |
2024-07 | PHASE2 |
| NCT07302841 | NOT_YET_RECRUITING | Pancreatic Cancer Non-resectable |
Tianjin Medical University Cancer Institute and Hospital |
2026-01-20 | PHASE4 |
| NCT06851247 | RECRUITING | Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2025-01-03 | PHASE2 |
| NCT04999761 | RECRUITING | Advanced or Metastatic Solid Tumor; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Gastric Cancer; Alveolar Soft Part Sarcoma; Esophageal Cancer; Head and Neck Cancer; Biliary Tract Cancer |
Taiho Pharmaceutical Co., Ltd. |
2021-06-01 | PHASE1 |
| NCT06710288 | RECRUITING | Platinum-resistant Ovarian Cancer |
ImmunityBio, Inc. |
2024-11-06 | PHASE2 |
| NCT02151084 | ACTIVE_NOT_RECRUITING | Biliary Tract Carcinoma; Gallbladder Carcinoma |
University Health Network, Toronto |
2014-11 | PHASE2 |
| NCT05999994 | RECRUITING | Neoplasms; Child; Adolescent |
Eli Lilly and Company |
2020-01-22 | PHASE2 |
| NCT06888674 | NOT_YET_RECRUITING | Pancreatic Cancer Resectable |
Zhejiang University |
2025-04-01 | PHASE1; PHASE2 |
| NCT06494514 | RECRUITING | Locally Advanced Pancreatic Cancer |
Du Juan |
2024-04-01 | |
| NCT05101551 | RECRUITING | Acute Myeloid Leukemia |
Norman J. Lacayo |
2023-02-23 | PHASE1 |
| NCT07549958 | RECRUITING | Pancreatic Cancer; Pancreatic Cancer Metastatic |
University of California, Irvine |
2026-03-24 | PHASE1 |
| NCT04158635 | SUSPENDED | Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma |
City of Hope Medical Center |
2021-09-01 | PHASE1 |
| NCT06983210 | RECRUITING | Urothelial Carcinoma Bladder; Urothelial Carcinoma of the Renal Pelvis and Ureter; Urothelial Carcinoma Urethra; Urothelial Carcinoma Recurrent |
Nagoya University |
2025-05-01 | PHASE2 |
| NCT06239727 | RECRUITING | Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2024-03-01 | PHASE3 |
| NCT05497778 | ACTIVE_NOT_RECRUITING | Pancreas Cancer |
M.D. Anderson Cancer Center |
2022-10-21 | PHASE1 |
| NCT06770452 | RECRUITING | Metastatic Pancreatic Carcinoma |
Zhejiang University |
2025-03-25 | PHASE2 |
| NCT04241185 | ACTIVE_NOT_RECRUITING | Urinary Bladder Neoplasms |
Merck Sharp & Dohme LLC |
2020-05-19 | PHASE3 |
| NCT06234072 | NOT_YET_RECRUITING | Pancreatic Cancer |
Shenzhen University General Hospital |
2024-02 | PHASE2 |
| NCT05823311 | RECRUITING | Advanced Cholangiocarcinoma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2023-09-01 | PHASE3 |
| NCT05969171 | RECRUITING | Pancreatic Cancer Metastatic |
Fudan University |
2023-12-05 | PHASE2 |
| NCT07025174 | RECRUITING | Bile Duct Carcinoma; Gall Bladder Cancer; Biliary Tract Cancer; Cholangiocarcinoma |
First Affiliated Hospital of Zhejiang University |
2025-06-01 | PHASE2 |
| NCT07014943 | RECRUITING | Primary Central Nervous System Lymphoma (PCNSL) |
Sichuan University |
2022-01-01 | PHASE2 |
| NCT05668884 | RECRUITING | Biliary Tract Carcinoma |
Fudan University |
2022-10-18 | PHASE2 |
| NCT05653453 | RECRUITING | Locally Advanced Pancreatic Cancer |
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd |
2022-12-20 | PHASE3 |
| NCT05281471 | RECRUITING | Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High-grade Serous Ovarian Cancer; Endometrioid Ovarian Cancer; Ovarian Clear Cell Carcinoma |
Genelux Corporation |
2022-08-31 | PHASE3 |
| NCT06623162 | NOT_YET_RECRUITING | Mibc; Muscle Invasive Bladder Cancer |
Fundación de investigación HM |
2024-12 | PHASE2 |
| NCT06202261 | RECRUITING | Metastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignancies |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2023-04-13 | PHASE1; PHASE2 |
| NCT06156514 | RECRUITING | Locally Advanced Cervical Cancer; Gemcitabine; Chemo-radiotherapy |
National Institute of Cancerología |
2019-11-06 | PHASE3 |
| NCT06611345 | RECRUITING | Biliary Tract Cancers (BTC) |
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd |
2024-10-21 | |
| NCT06447662 | ACTIVE_NOT_RECRUITING | Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Pfizer |
2024-06-27 | PHASE1 |
| NCT05451043 | RECRUITING | Pancreatic Cancer; Hepatocellular Cancer; Biliary Tract Cancer; Cholangiocarcinoma |
AHS Cancer Control Alberta |
2023-07-05 | PHASE2 |
| NCT03440450 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumors; Biliary Tract Cancer |
Fujifilm Pharmaceuticals U.S.A., Inc. |
2018-03-22 | PHASE1 |
| NCT06114225 | RECRUITING | Osteosarcoma |
Ruijin Hospital |
2023-06-01 | PHASE2 |
| NCT07138989 | NOT_YET_RECRUITING | Nasopharyngeal Cancinoma (NPC) |
Sun Yat-sen University |
2025-08-19 | PHASE2 |
| NCT04966663 | RECRUITING | Non Small Cell Lung Cancer; Complete Surgical Resection; Circulating Tumor DNA |
University Health Network, Toronto |
2022-03-28 | PHASE2 |
| NCT06584227 | RECRUITING | Pancreatic Cancer, Adult |
Liu Xiufeng |
2024-09-10 | PHASE2 |
| NCT05065957 | RECRUITING | Biliary Tract Cancer |
InnoPharmax Inc. |
2022-03-29 | PHASE2; PHASE3 |
| NCT06162468 | NOT_YET_RECRUITING | Intraductal Papillary Mucinous Neoplasm of Pancreas |
University of Auckland, New Zealand |
2025-05-31 | |
| NCT06704724 | TERMINATED | Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Pfizer |
2024-12-10 | PHASE1 |
| NCT06398587 | WITHDRAWN | Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma |
OHSU Knight Cancer Institute |
2024-08-01 | PHASE2 |
| NCT04481204 | WITHDRAWN | Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma |
M.D. Anderson Cancer Center |
2023-04-18 | PHASE2 |
| NCT06886347 | RECRUITING | Metastatic Nasopharyngeal Carcinoma |
Chen Xiaozhong |
2023-07-07 | PHASE1 |
| NCT05211323 | ACTIVE_NOT_RECRUITING | Combined Hepatocellular Carcinoma and Cholangiocarcinoma; Stage III Liver Cancer; Stage IV Liver Cancer |
National Cancer Institute (NCI) |
2022-12-07 | PHASE2 |
| NCT06916494 | RECRUITING | Muscle Invasive Bladder Cancer |
First Affiliated Hospital of Chongqing Medical University |
2025-05-01 | PHASE1 |
| NCT06382142 | ACTIVE_NOT_RECRUITING | Triple-Negative Breast Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2024-06-21 | PHASE3 |
| NCT05241249 | RECRUITING | Pancreas Cancer |
Susan E. Bates |
2022-02-01 | PHASE2 |
| NCT06375915 | UNKNOWN | Intrahepatic Cholangiocarcinoma |
Francesco De Cobelli |
2024-05-01 | PHASE2 |
| NCT05466318 | UNKNOWN | Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell |
Sichuan University |
2022-07-01 | PHASE3 |
| NCT06076837 | TERMINATED | Pancreatic Cancer Metastatic; Pancreatic Adenocarcinoma Metastatic |
HonorHealth Research Institute |
2025-01-09 | PHASE1 |
| NCT02170090 | ACTIVE_NOT_RECRUITING | Cholangiocarcinoma; Gall Bladder Carcinoma |
Universitätsklinikum Hamburg-Eppendorf |
2014-04 | PHASE3 |
| NCT06326736 | RECRUITING | Pancreatic Cancer |
Jinling Hospital, China |
2024-04 | EARLY_PHASE1 |
| NCT02705196 | COMPLETED | Pancreatic Cancer |
Lokon Pharma AB |
2016-11 | PHASE1; PHASE2 |
| NCT05527470 | RECRUITING | Nasopharyngeal Carcinoma |
Wei Jiang |
2022-11-11 | PHASE3 |
| NCT06164327 | UNKNOWN | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
BeBetter Med Inc |
2023-12-01 | PHASE1 |
| NCT06086197 | RECRUITING | Diffuse Large B-cell Lymphoma Recurrent; Diffuse Large B Cell Lymphoma Refractory |
Zhejiang Cancer Hospital |
2023-10-01 | PHASE2 |
| NCT05754853 | RECRUITING | Advanced or Metastatic Urothelium Cancer |
Shanghai Miracogen Inc. |
2023-04-06 | PHASE3 |
| NCT06018883 | UNKNOWN | Metastatic Pancreatic Adenocarcinoma |
Fudan University |
2023-08-20 | PHASE3 |
| NCT05813626 | ACTIVE_NOT_RECRUITING | Nasopharyngeal Carcinoma |
Zhejiang Cancer Hospital |
2023-04-21 | PHASE2 |
| NCT01261728 | COMPLETED | Urothelial Carcinoma |
Memorial Sloan Kettering Cancer Center |
2010-12-14 | PHASE2 |
| NCT05325281 | TERMINATED | Pancreas Adenocarcinoma |
Medical College of Wisconsin |
2022-10-31 | PHASE1 |
| NCT03101995 | RECRUITING | Cervical Cancer |
National Institute of Cancerología |
2018-01-16 | PHASE2 |
| NCT06051851 | UNKNOWN | Pancreatic Adenocarcinoma Metastatic |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2023-07-01 | PHASE2 |
| NCT05185869 | UNKNOWN | Pancreatic Cancer |
Ruijin Hospital |
2022-01 | PHASE2 |
| NCT03918278 | COMPLETED | Neoplasms |
Merck Sharp & Dohme LLC |
2019-06-19 | PHASE1 |
| NCT05189028 | UNKNOWN | Cervical Cancer; Neoadjuvant Chemotherapy |
Chuangzhen Chen |
2021-07-01 | PHASE3 |
| NCT04877587 | WITHDRAWN | Soft Tissue Sarcoma; Bone Sarcoma; Unresectable Soft Tissue Sarcoma; Metastatic Bone Sarcoma; Metastatic Soft-tissue Sarcoma; Unresectable Bone Sarcoma |
David Dickens |
2023-01 | EARLY_PHASE1 |
| NCT05908747 | COMPLETED | Pancreatic Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2023-05-31 | PHASE2 |
| NCT06472037 | UNKNOWN | Locally Advanced Pancreatic Ductal Adenocarcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2024-07-01 | PHASE2 |
| NCT04898374 | UNKNOWN | Nasopharyngeal Carcinoma |
Kuwait Cancer Control Center |
2021-05-01 | PHASE3 |
| NCT03088540 | COMPLETED | Carcinoma，Non-Small-Cell Lung; Lung Carcinomas, Non-Small-Cell; Non-small-cell Lung Carcinoma; Nonsmall Cell Lung Cancer |
Regeneron Pharmaceuticals |
2017-05-29 | PHASE3 |
| NCT05673811 | COMPLETED | Pancreatic Adenocarcinoma; Metastatic |
Theriva Biologics SL |
2023-01-10 | PHASE2 |
| NCT04832854 | TERMINATED | Non-Small Cell Lung Cancer (NSCLC) |
Hoffmann-La Roche |
2021-04-23 | PHASE2 |
| NCT03002103 | SUSPENDED | Triple-Negative Breast Cancer |
SynCore Biotechnology Co., Ltd. |
2016-11-23 | PHASE3 |
| NCT05171647 | ACTIVE_NOT_RECRUITING | Non-Hodgkin Lymphoma |
Hoffmann-La Roche |
2022-04-25 | PHASE3 |
| NCT04222972 | TERMINATED | RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Diseases; Head and Neck Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue |
Hoffmann-La Roche |
2020-07-24 | PHASE3 |
| NCT04617756 | RECRUITING | Urothelial Carcinoma; Cancer |
Centre Hospitalier Universitaire de Nīmes |
2021-09-29 | PHASE2 |
| NCT02203760 | ACTIVE_NOT_RECRUITING | Leiomyosarcoma or Carcinosarcoma |
North Eastern German Society of Gynaecological Oncology |
2019-10-16 | PHASE2 |
| NCT04371224 | UNKNOWN | Pancreatic Cancer |
Seoul National University Hospital |
2020-06-23 | PHASE2 |
| NCT05312840 | COMPLETED | Non Small Cell Lung Cancer |
People's Hospital of Quzhou |
2022-01-01 | PHASE4 |
| NCT04447092 | UNKNOWN | Pancreatic Cancer; Chemotherapy Effect |
Seoul National University Hospital |
2020-07-01 | PHASE2 |
| NCT05178628 | UNKNOWN | Pancreatic Cancer; Thromboembolism |
Michalis Karamouzis |
2022-02-10 | PHASE3 |
| NCT05576272 | UNKNOWN | Nasopharyngeal Carcinoma |
Qilu Pharmaceutical Co., Ltd. |
2022-05-19 | PHASE2; PHASE3 |
| NCT05651269 | UNKNOWN | NSCLC |
Tiziana Life Sciences LTD |
2023-03-15 | PHASE2 |
| NCT02969083 | UNKNOWN | Upper Tract Urothelial Carcinoma |
The European Uro-Oncology Group |
2018-05-28 | PHASE2 |
| NCT05991518 | UNKNOWN | HER2 Gene Mutation |
SUNHO（China）BioPharmaceutical CO., Ltd. |
2023-04-25 | PHASE1; PHASE2 |
| NCT05717790 | RECRUITING | Nasopharyngeal Carcinoma by AJCC V8 Stage |
Fourth Affiliated Hospital of Guangxi Medical University |
2022-12-01 | |
| NCT04787991 | COMPLETED | Metastatic Pancreatic Adenocarcinoma |
Cancer Insight, LLC |
2021-08-09 | PHASE1 |
| NCT03750669 | COMPLETED | Pancreatic Adenocarcinoma Resectable; Neoadjuvant Chemotherapy |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2018-10-20 | PHASE3 |
| NCT03673072 | COMPLETED | Incidental Gallbladder Carcinoma; Biliary Tract Cancer |
Krankenhaus Nordwest |
2019-07-01 | PHASE3 |
| NCT03366415 | UNKNOWN | Nasopharyngeal Carcinoma |
Chaosu Hu |
2018-01-01 | PHASE3 |
| NCT06533722 | COMPLETED | HER2-negative Metastatic Breast Cancer |
Sun Yat-sen University |
2024-08-04 | PHASE2 |
| NCT05580445 | UNKNOWN | Advanced Pancreatic Cancer |
Shouyao Holdings (Beijing) Co. LTD |
2022-08-11 | PHASE1; PHASE2 |
| NCT05415917 | WITHDRAWN | Pancreatic Cancer |
Rutgers, The State University of New Jersey |
2022-07-29 | PHASE2 |
| NCT04643405 | TERMINATED | Advanced Pancreatic Cancer |
Ascentage Pharma Group Inc. |
2021-03-17 | PHASE1; PHASE2 |
| NCT04247165 | COMPLETED | Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer |
Herlev Hospital |
2020-06-02 | PHASE1; PHASE2 |
| NCT04799249 | COMPLETED | TNBC - Triple-Negative Breast Cancer; Breast Cancer |
G1 Therapeutics, Inc. |
2021-05-14 | PHASE3 |
| NCT04289792 | UNKNOWN | Pancreatic Neoplasms |
Fujian Medical University Union Hospital |
2020-05-09 | PHASE2 |
| NCT03789864 | TERMINATED | Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides |
Indiana University |
2019-10-07 | |
| NCT04203160 | TERMINATED | Biliary Tract Cancer |
University of Michigan Rogel Cancer Center |
2020-06-23 | PHASE1; PHASE2 |
| NCT06320301 | Recruiting | Biliary Tract Cancer|Gemox Chemotherapy |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Suzhou Suncadia Biopharmaceuticals Co. Ltd. |
2024-04-01 | Phase 2 |
| NCT02885974 | COMPLETED | Bladder Cancer |
Baylor College of Medicine |
2016-12 | PHASE1 |
| NCT06046794 | Not yet recruiting | Cancer Of Pancreas |
Institut Paoli-Calmettes |
2024-02-01 | Not Applicable |
| NCT04156087 | COMPLETED | Pancreatic Cancer Non-resectable |
Baki Topal |
2020-05-09 | PHASE2 |
| NCT05186558 | UNKNOWN | Lymphoma, Large B-Cell, Diffuse; Neoplasms by Histologic Type |
The First Affiliated Hospital with Nanjing Medical University |
2022-05-15 | PHASE2 |
| NCT06199466 | Recruiting | Metastatic Pancreatic Cancer |
M.D. Anderson Cancer Center|280Bio Inc |
2024-01-22 | Phase 1 |
| NCT04890522 | NOT_YET_RECRUITING | Nasopharyngeal Carcinoma; Metastasis; Chemotherapy; Immunotherapy; Survival |
Sun Yat-sen University |
2021-07-01 | PHASE2; PHASE3 |
| NCT01972919 | COMPLETED | Unresectable Pancreatic Cancer |
Medical College of Wisconsin |
2015-12-10 | PHASE2 |
| NCT04668976 | UNKNOWN | Colorectal Cancer; Cholangiocarcinoma |
Benaroya Research Institute |
2020-11-25 | PHASE2 |
| NCT00657878 | UNKNOWN | Ovarian Cancer |
National Cancer Institute, Naples |
2008-11 | PHASE3 |
| NCT04871529 | TERMINATED | Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall; Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma; Stage II Bladder Cancer AJCC v8 |
SWOG Cancer Research Network |
2022-08-10 | PHASE2 |
| NCT06055348 | Not yet recruiting | Serous Ovarian Cancer|Advanced Ovarian Cancer |
Biocity Biopharmaceutics Co. Ltd. |
2023-10-30 | Phase 1|Phase 2 |
| NCT05030077 | UNKNOWN | Urothelial Carcinoma; Anlotinib; Urogenital Neoplasms; Cisplatin; Carboplatin; Gemcitabine; Antineoplastic Agents |
Tianjin Medical University Second Hospital |
2021-10-01 | PHASE2 |
| NCT05138159 | UNKNOWN | Metastatic Pancreatic Cancer |
Fudan University |
2021-12-01 | PHASE2 |
| NCT04023669 | COMPLETED | Brain Tumor; Brain Tumor, Recurrent; Brain Tumor, Refractory; Brain Tumor, Pediatric; Medulloblastoma; Medulloblastoma Recurrent; Medulloblastoma, Non-WNT/Non-SHH; Medulloblastoma, Non-WNT/Non-SHH, Group 3; Medulloblastoma, Non-WNT/Non-SHH, Group 4; Brain Cancer; CNS Cancer; CNS Tumor; CNS Neoplasm |
St. Jude Children's Research Hospital |
2019-08-08 | PHASE1 |
| NCT03260712 | COMPLETED | Biliary Tract Cancer; Metastatic Cancer; Advanced Cancer; Gallbladder Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
2020-01-07 | PHASE2 |
| NCT03435250 | TERMINATED | Advanced Solid Tumors; Lymphoma |
Institut de Recherches Internationales Servier |
2018-03-04 | PHASE1 |
| NCT04887831 | TERMINATED | Urothelial Carcinoma; Bladder Cancer; Myelosuppression Adult; Chemotherapy-induced Neutropenia; Metastatic Bladder Cancer |
G1 Therapeutics, Inc. |
2021-06-04 | PHASE2 |
| NCT04948788 | UNKNOWN | Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma |
Jiangsu HengRui Medicine Co., Ltd. |
2021-10 | PHASE2 |
| NCT07411144 | COMPLETED | Diffuse Pleural Mesothelioma (DPM) |
National Cancer Institute, Egypt |
2020-03-15 | PHASE2 |
| NCT04846634 | NOT_YET_RECRUITING | Resectable Locally Advanced Non-small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2021-08 | PHASE2 |
| NCT04405622 | UNKNOWN | Nasopharyngeal Carcinoma; Recurrent Nasopharyngeal Carcinoma; Metastatic Nasopharyngeal Carcinoma; Chemotherapy Effect; Immunotherapy |
Sun Yat-sen University |
2020-05-30 | PHASE2 |
| NCT02167711 | COMPLETED | Cholangio Carcinoma |
Chinese University of Hong Kong |
2014-09-17 | PHASE2 |
| NCT03251313 | UNKNOWN | Triple Negative Breast Cancer |
Fudan University |
2019-05-15 | PHASE1 |
| NCT04331626 | UNKNOWN | Non-small Cell Lung Cancer Metastatic |
Henan Cancer Hospital |
2020-04 | PHASE4 |
| NCT03666832 | UNKNOWN | Metastatic Pancreatic Cancer |
Joon Oh Park |
2019-06-17 | PHASE1; PHASE2 |
| NCT04306900 | COMPLETED | Solid Tumor, Adult |
Trishula Therapeutics, Inc. |
2020-03-30 | PHASE1 |
| NCT02621151 | ACTIVE_NOT_RECRUITING | Muscle-invasive Urothelial Cancer of the Bladder |
NYU Langone Health |
2016-08-11 | PHASE2 |
| NCT04581343 | COMPLETED | Metastatic Pancreatic Ductal Adenocarcinoma |
Pancreatic Cancer Action Network |
2020-11-02 | PHASE1 |
| NCT04386746 | ACTIVE_NOT_RECRUITING | Urothelial Carcinoma Bladder; Bladder Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2020-07-29 | PHASE2 |
| NCT03535727 | COMPLETED | Adenocarcinoma; Pancreatic Neoplasms; Neoplasm, Glandular; Neoplasms; Neoplasms Pancreatic; Digestive System Neoplasm; Endocrine Gland Neoplasms; Digestive System Disease; Pancreatic Diseases; Endocrine System Diseases |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2018-06-21 | PHASE1; PHASE2 |
| NCT02426281 | COMPLETED | Pancreatic Ductal Adenocarcinoma |
Samsung Medical Center |
2015-06-04 | PHASE2 |
| NCT03432741 | TERMINATED | Breast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Recurrent Hodgkin Lymphoma; Recurrent Mycosis Fungoides; Recurrent Non-Hodgkin Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Breast Carcinoma; Refractory Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Nodal Marginal Zone Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Stage IV Breast Cancer AJCC v6 and v7 |
Mayo Clinic |
2018-03-27 | PHASE1 |
| NCT02635971 | UNKNOWN | Carcinoma, Pancreatic |
Fudan University |
2015-12 | PHASE2 |
| NCT04414566 | UNKNOWN | Nasopharyngeal Carcinoma |
West China Hospital |
2020-06-01 | PHASE3 |
| NCT03081039 | WITHDRAWN | Intrahepatic Cholangiocarcinoma |
University of Louisville |
2017-08-21 | PHASE3 |
| NCT03943667 | COMPLETED | Metastatic Pancreatic Adenocarcinoma |
UNICANCER |
2019-05-23 | PHASE3 |
| NCT03519308 | TERMINATED | Pancreatic Cancer |
Abramson Cancer Center at Penn Medicine |
2020-07-29 | EARLY_PHASE1 |
| NCT04480190 | WITHDRAWN | Cholangiocarcinoma; Biliary Cancer |
Jordan Kharofa |
2021-02-04 | PHASE1 |
| NCT03539328 | UNKNOWN | Ovarian Cancer |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2018-06 | PHASE2 |
| NCT03674242 | TERMINATED | Triple Negative Breast Cancer |
ERYtech Pharma |
2019-06-13 | PHASE2; PHASE3 |
| NCT03737123 | TERMINATED | Urothelial Carcinoma |
Nabil Adra |
2018-12-19 | PHASE2 |
| NCT02564146 | COMPLETED | Metastatic Pancreatic Cancer; Adenocarcinoma of the Pancreas |
AIO-Studien-gGmbH |
2016-12 | PHASE2 |
| NCT02578641 | COMPLETED | Nasopharyngeal Carcinoma |
Tessa Therapeutics |
2014-07 | PHASE3 |
| NCT04470076 | UNKNOWN | Non Small Cell Lung Cancer; Surgery; EGFR Activating Mutation; Chemotherapy; EGFR TKI |
Fifth Affiliated Hospital, Sun Yat-Sen University |
2020-07-10 | PHASE2 |
| NCT01897454 | TERMINATED | Pancreatic Adenocarcinoma; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer |
Albert Einstein College of Medicine |
2012-01-27 | PHASE2 |
| NCT00370890 | COMPLETED | Nasopharyngeal Cancer |
Chinese University of Hong Kong |
2006-09-04 | PHASE3 |
| NCT04313608 | COMPLETED | B-cell Lymphoma |
Hoffmann-La Roche |
2020-06-04 | PHASE1 |
| NCT02611037 | COMPLETED | Malignant Pleural Mesothelioma; Mesothelioma |
H. Lee Moffitt Cancer Center and Research Institute |
2016-03-04 | PHASE2 |
| NCT03703063 | UNKNOWN | Pancreatic Adenocarcinoma |
Benaroya Research Institute |
2018-09-17 | PHASE1 |
| NCT02918747 | UNKNOWN | Lymphoma |
Hunan Cancer Hospital |
2016-09 | PHASE2 |
| NCT02926183 | UNKNOWN | Pancreatic Ductal Adenocarcinoma |
Wakayama Medical University |
2016-10 | PHASE2 |
| NCT03707509 | UNKNOWN | Nasopharyngeal Carcinoma |
Jiangsu HengRui Medicine Co., Ltd. |
2018-11-13 | PHASE3 |
| NCT03071822 | UNKNOWN | Peripheral T Cell Lymphoma |
The University of Hong Kong |
2017-02-24 | PHASE4 |
| NCT02822157 | UNKNOWN | Ovarian Epithelial Cancer |
Universitaire Ziekenhuizen KU Leuven |
2016-08 | PHASE2 |
| NCT04917250 | UNKNOWN | Extranodal NK/T-cell Lymphoma |
Beijing Tongren Hospital |
2020-03-20 | PHASE2 |
| NCT02550327 | COMPLETED | Pancreatic Adenocarcinoma |
Baylor Research Institute |
2016-01 | EARLY_PHASE1 |
| NCT03684811 | COMPLETED | Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme); Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas); Cohort 3a and 3b: Chondrosarcoma; Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma; Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations |
Forma Therapeutics, Inc. |
2018-11-01 | PHASE1; PHASE2 |
| NCT04066491 | TERMINATED | Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer |
EMD Serono Research & Development Institute, Inc. |
2019-09-20 | PHASE2; PHASE3 |
| NCT04299880 | COMPLETED | Oncology |
Sumitomo Pharma America, Inc. |
2020-02-24 | PHASE1 |
| NCT06440187 | COMPLETED | Recurrent or Metastatic Nasopharyngeal Carcinom |
Seoul National University Hospital |
2018-06-08 | PHASE2 |
| NCT03488251 | TERMINATED | Non-hodgkin Lymphoma,B Cell; Refractory Diffuse Large B-Cell Lymphoma; Relapsed Diffuse Large B-Cell Lymphoma |
Molecular Templates, Inc. |
2018-08-20 | PHASE2 |
| NCT03214250 | COMPLETED | Metastatic Pancreatic Adenocarcinoma |
Parker Institute for Cancer Immunotherapy |
2017-07-21 | PHASE1; PHASE2 |
| NCT04054362 | COMPLETED | Pancreatic Cancer |
Barts & The London NHS Trust |
2018-11-29 | PHASE2 |
| NCT03086369 | COMPLETED | Metastatic Pancreatic Cancer |
Eli Lilly and Company |
2017-06-22 | PHASE1; PHASE2 |
| NCT03366766 | TERMINATED | Non-Squamous Non-Small Cell Lung Carcinoma; Stage I Non-Small Cell Lung Cancer; Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage II Non-Small Cell Lung Cancer; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2017-12-20 | PHASE2 |
| NCT04750382 | UNKNOWN | Triple-negative Breast Cancer |
Taizhou Hanzhong biomedical co. LTD |
2019-07-15 | PHASE1; PHASE2 |
| NCT02490488 | COMPLETED | Ovarian Cancer |
AB Science |
2014-04 | PHASE2; PHASE3 |
| NCT02627807 | UNKNOWN | Nasopharyngeal Neoplasms |
Sun Yat-sen University |
2015-12 | |
| NCT03717155 | COMPLETED | Squamous Non-Small Cell Lung Cancer |
Merck KGaA, Darmstadt, Germany |
2018-10-30 | PHASE2 |
| NCT01595061 | UNKNOWN | Stage III Vulvar Cancer AJCC v7; Stage IIIA Vulvar Cancer AJCC v7; Stage IIIB Vulvar Cancer AJCC v7; Stage IIIC Vulvar Cancer AJCC v7; Stage IVA Vulvar Cancer AJCC v7; Vulvar Squamous Cell Carcinoma |
Gynecologic Oncology Group |
2012-07-02 | PHASE2 |
| NCT00769483 | COMPLETED | Pancreatic Cancer; Pancreatic Adenocarcinoma |
M.D. Anderson Cancer Center |
2008-11-13 | PHASE1; PHASE2 |
| NCT02392637 | COMPLETED | Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma |
M.D. Anderson Cancer Center |
2015-04-02 | PHASE2 |
| NCT03486678 | COMPLETED | Biliary Tract Cancer; Cholangiocarcinoma |
The First Affiliated Hospital with Nanjing Medical University |
2018-02-10 | PHASE2 |
| NCT03636308 | UNKNOWN | Pancreatic Cancer |
Peking University |
2018-07-17 | PHASE2 |
| NCT03601975 | UNKNOWN | Nasopharyngeal Carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2018-08-27 | PHASE3 |
| NCT03517176 | COMPLETED | Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma |
Lisata Therapeutics, Inc. |
2018-07-31 | PHASE1 |
| NCT03559348 | COMPLETED | Pancreatic Adenocarcinoma |
National Health Research Institutes, Taiwan |
2018-04-03 | PHASE2 |
| NCT02993731 | COMPLETED | Carcinoma, Pancreatic Ductal |
Sumitomo Pharma America, Inc. |
2016-12 | PHASE3 |
| NCT02363751 | COMPLETED | Collecting Duct Carcinoma (Kidney) |
UNICANCER |
2014-12 | PHASE2 |
| NCT03464968 | COMPLETED | Biliary Cancer Metastatic |
Seoul National University Bundang Hospital |
2015-07-29 | PHASE2 |
| NCT03628521 | UNKNOWN | Lung Cancer; Advanced Stage |
Shanghai Chest Hospital |
2018-07-20 | PHASE1 |
| NCT02009332 | COMPLETED | Non-muscle Invasive Bladder Cancer (NMIBC) |
Aadi Bioscience, Inc. |
2014-04-09 | PHASE1; PHASE2 |
| NCT02427841 | COMPLETED | Pancreatic Adenocarcinoma; Resectable Pancreatic Carcinoma |
OHSU Knight Cancer Institute |
2016-01-21 | PHASE2 |
| NCT01270724 | COMPLETED | CNS Germ Cell Tumor |
Nationwide Children's Hospital |
2010-08 | PHASE2 |
| NCT05517239 | COMPLETED | Hepatocellular Carcinoma, Unresectable, Advanced |
Yonsei University |
2015-05-01 | PHASE2 |
| NCT02878889 | UNKNOWN | Nasopharyngeal Carcinoma |
Zhejiang Cancer Hospital |
2016-08 | PHASE2 |
| NCT03344172 | TERMINATED | Pancreatic Cancer Resectable |
Nathan Bahary, MD |
2017-12-13 | PHASE2 |
| NCT03236883 | UNKNOWN | Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV |
Tianjin Medical University Cancer Institute and Hospital |
2016-04 | PHASE1 |
| NCT03307148 | COMPLETED | Pancreatic Adenocarcinoma |
Barts & The London NHS Trust |
2016-01-15 | PHASE1 |
| NCT01309633 | COMPLETED | Nasopharyngeal Carcinoma |
National University Hospital, Singapore |
2011-09-02 | PHASE2 |
| NCT01077427 | UNKNOWN | Resected Pancreatic Adenocarcinoma |
Klinikum der Universitaet Muenchen, Grosshadern |
2012-03 | PHASE3 |
| NCT02162914 | UNKNOWN | Cholangiocarcinoma |
Erasme University Hospital |
2014-03-14 | PHASE2 |
| NCT03432598 | COMPLETED | Locally Advanced Lung Cancer; Metastatic Lung Cancer |
BeiGene |
2017-08-24 | PHASE2 |
| NCT02272790 | COMPLETED | Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation |
AstraZeneca |
2015-01-30 | PHASE2 |
| NCT03848182 | TERMINATED | Pancreatic Cancer |
Albert Einstein College of Medicine |
2017-07-21 | PHASE2 |
| NCT01872962 | UNKNOWN | Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2013-11 | PHASE3 |
| NCT02453282 | ACTIVE_NOT_RECRUITING | Non-Small-Cell Lung Carcinoma NSCLC |
AstraZeneca |
2015-07-21 | PHASE3 |
| NCT02114502 | WITHDRAWN | Myeloma |
M.D. Anderson Cancer Center |
2014-09 | PHASE2 |
| NCT02412670 | COMPLETED | High Grade Upper Tract Urothelial Carcinoma |
ECOG-ACRIN Cancer Research Group |
2015-08-27 | PHASE2 |
| NCT01589094 | COMPLETED | Bladder Cancer |
Memorial Sloan Kettering Cancer Center |
2012-04 | PHASE2 |
| NCT03560973 | COMPLETED | Mesothelioma |
Gruppo Oncologico Italiano di Ricerca Clinica |
2016-12-22 | PHASE2 |
| NCT02375880 | COMPLETED | Carcinoma of Intrahepatic and Extra-hepatic Biliary System; Carcinoma of Gallbladder; Bile Duct Cancer; Cholangiocarcinoma |
Leap Therapeutics, Inc. |
2015-06 | PHASE1 |
| NCT02767752 | TERMINATED | Pancreatic Cancer |
Herlev Hospital |
2016-11 | PHASE2 |
| NCT01726582 | COMPLETED | Pancreatic Adenocarcinoma |
Medical College of Wisconsin |
2011-11 | PHASE2 |
| NCT02487277 | TERMINATED | Adenocarcinoma |
Andrew Ko |
2015-07-14 | PHASE2 |
| NCT01442662 | COMPLETED | Leiomyosarcoma |
UNICANCER |
2011-09 | PHASE2 |
| NCT02559674 | COMPLETED | Advanced Pancreatic Cancer |
Altor BioScience |
2016-07 | PHASE1 |
| NCT01376310 | TERMINATED | Cancer |
Novartis Pharmaceuticals |
2010-11-02 | PHASE2 |
| NCT02791373 | COMPLETED | Multiple Myeloma; Amyloidosis |
Insel Gruppe AG, University Hospital Bern |
2014-03 | PHASE2 |
| NCT00997906 | UNKNOWN | Head and Neck Cancer |
National Cancer Centre, Singapore |
2009-09-15 | PHASE2; PHASE3 |
| NCT02409355 | TERMINATED | Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
2015-05-07 | PHASE3 |
| NCT01971281 | UNKNOWN | Pancreatic Adenocarcinoma |
NovoCure Ltd. |
2013-11 | PHASE1; PHASE2 |
| NCT02558868 | COMPLETED | Pancreatic Neoplasms |
Zhejiang University |
2015-09-01 | PHASE2 |
| NCT02300610 | COMPLETED | Bladder Cancer; Carcinoma, Transitional Cell; Renal Pelvis Cancer; Ureter Cancer; Urethra Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2015-02-11 | PHASE1 |
| NCT01524991 | COMPLETED | Urothelial Carcinoma |
Hoosier Cancer Research Network |
2012-01 | PHASE2 |
| NCT01908478 | COMPLETED | Pancreatic Cancer |
Cedars-Sinai Medical Center |
2013-10-02 | PHASE1 |
| NCT02506803 | UNKNOWN | Pancreatic Cancer |
Wakayama Medical University |
2015-07 | PHASE1 |
| NCT01259063 | COMPLETED | Bladder Cancer |
Memorial Sloan Kettering Cancer Center |
2010-12 | PHASE1; PHASE2 |
| NCT02425137 | COMPLETED | Advanced Biliary Tract Cancer(BTC) |
TTY Biopharm |
2015-04 | PHASE2 |
| NCT02514421 | COMPLETED | Pancreatic Adenocarcinoma |
The University of Texas Health Science Center, Houston |
2015-07 | PHASE1 |
| NCT02440958 | COMPLETED | Pancreatic Ductal Adenocarcinoma |
Yonsei University |
2015-08-28 | PHASE2 |
| NCT02632019 | UNKNOWN | Advanced Biliary Tract Malignant Tumor |
Second Military Medical University |
2015-09 | PHASE1; PHASE2 |
| NCT01352962 | COMPLETED | Urethral Neoplasms; Neoplasms, Urethral; Cancer of the Urethra; Urethral Cancer |
National Cancer Institute (NCI) |
2011-09-26 | PHASE1 |
| NCT02005419 | COMPLETED | Stage IA Pancreatic Adenocarcinoma; Stage IB Pancreatic Adenocarcinoma; Stage IIA Pancreatic Adenocarcinoma; Stage IIB Pancreatic Adenocarcinoma |
Xian-Jun Yu |
2013-12 | PHASE2 |
| NCT01041781 | TERMINATED | Lung Cancer |
Alliance for Clinical Trials in Oncology |
2010-02 | PHASE3 |
| NCT02651727 | TERMINATED | Pancreatic Cancer |
Verastem, Inc. |
2015-09 | PHASE1 |
| NCT02900742 | COMPLETED | Cancer |
Shanghai University of Traditional Chinese Medicine |
2013-03 | PHASE3 |
| NCT02581501 | WITHDRAWN | Pancreatic Cancer |
Stamford Hospital |
2016-02 | PHASE1 |
| NCT02850874 | WITHDRAWN | Pancreatic Neoplasms; Pancreatic Adenocarcinoma |
Wake Forest University Health Sciences |
2016-02 | PHASE2 |
| NCT02207335 | UNKNOWN | Metastatic Breast Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2013-12 | PHASE3 |
| NCT01836432 | TERMINATED | Pancreatic Cancer; Pancreatic Carcinoma Non-resectable; Locally Advanced Malignant Neoplasm |
NewLink Genetics Corporation |
2013-05 | PHASE3 |
| NCT01846390 | COMPLETED | Peripheral T-Cell Lymphoma; Diffuse Large B-Cell Lymphoma |
Canadian Cancer Trials Group |
2013-10-01 | PHASE1 |
| NCT02117258 | COMPLETED | Metastatic Pancreatic Adenocarcinoma |
Zeria Pharmaceutical |
2014-04 | PHASE2 |
| NCT01549093 | UNKNOWN | Non-small Cell Lung Cancer |
Hunan Province Tumor Hospital |
2011-08 | PHASE2 |
| NCT02405585 | TERMINATED | Pancreatic Cancer; Pancreatic Carcinoma Non-resectable |
NewLink Genetics Corporation |
2015-04 | PHASE2 |
| NCT02099396 | UNKNOWN | Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma |
China Association of Osteosarcoma Chemotherapy |
2014-04 | PHASE2; PHASE3 |
| NCT01893801 | COMPLETED | Stage IV Pancreatic Cancer |
Pancreatic Cancer Research Team |
2013-05 | PHASE1; PHASE2 |
| NCT02570711 | TERMINATED | Metastatic Pancreatic Cancer |
Acerta Pharma BV |
2015-10-13 | PHASE2 |
| NCT02245217 | COMPLETED | Pancreatic Cancer |
University of Utah |
2014-12-12 | |
| NCT01206049 | COMPLETED | Cholangiocarcinoma |
Vejle Hospital |
2010-09 | PHASE2 |
| NCT01182168 | COMPLETED | Bladder Cancer; Renal Pelvis Cancer; Ureter Cancer |
Memorial Sloan Kettering Cancer Center |
2010-08 | PHASE1 |
| NCT02182778 | COMPLETED | Biliary Tract Cancer |
Kansai Hepatobiliary Oncology Group |
2014-07-09 | PHASE3 |
| NCT01746979 | COMPLETED | Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma |
ImmunoGenesis |
2012-12 | PHASE3 |
| NCT01858883 | COMPLETED | Solid Tumors; Pancreatic Cancer |
Incyte Corporation |
2013-06 | PHASE1; PHASE2 |
| NCT01702714 | WITHDRAWN | Non-Squamous Non-Small Cell Lung Cancer |
Hoffmann-La Roche |
2014-07 | PHASE1 |
| NCT01917617 | COMPLETED | Biliary Tract Cancer |
Kansai Hepatobiliary Oncology Group |
2013-05-22 | PHASE2 |
| NCT01501149 | UNKNOWN | Nasal and Nasal-type NK/T-cell Lymphoma |
Mingzhi Zhang |
2011-01 | PHASE4 |
| NCT01191892 | COMPLETED | Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Ureter Cancer; Urethral Cancer |
Cardiff University |
2010-06 | PHASE2 |
| NCT02233205 | UNKNOWN | Gastrointestinal Neoplasms |
Peking University Cancer Hospital & Institute |
2014-10 | PHASE1; PHASE2 |
| NCT01608711 | COMPLETED | Pancreatic Cancer; Carcinoma, Pancreatic Ductal; Pancreatic Disease |
Agensys, Inc. |
2012-08-07 | PHASE2 |
| NCT00733746 | COMPLETED | Pancreatic Cancer |
Alliance for Clinical Trials in Oncology |
2009-04 | PHASE2 |
| NCT00324805 | COMPLETED | Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7 |
National Cancer Institute (NCI) |
2007-07-19 | PHASE3 |
| NCT01411072 | UNKNOWN | Pancreas Cancer |
AHS Cancer Control Alberta |
2011-09 | |
| NCT01808638 | COMPLETED | Carcinoma, Pancreatic Ductal |
Silence Therapeutics GmbH |
2013-03 | PHASE1; PHASE2 |
| NCT01936974 | TERMINATED | Ovarian Carcinoma; Fallopian Tube Carcinoma; Peritoneal Carcinoma |
Western Regional Medical Center |
2013-09 | PHASE2 |
| NCT02105350 | WITHDRAWN | Biliary Tract Carcinoma; Gallbladder Carcinoma |
University Health Network, Toronto |
2015-06 | PHASE1 |
| NCT01303029 | COMPLETED | Metastatic Pancreatic Cancer |
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) |
2011-02 | PHASE2 |
| NCT01487915 | UNKNOWN | Advanced Urothelial Carcinoma |
Asan Medical Center |
2010-10 | PHASE2 |
| NCT02030574 | TERMINATED | Invasive Bladder Cancer; Bladder Cancer |
Brown University |
2014-07 | PHASE2 |
| NCT01510561 | WITHDRAWN | Metastatic Pancreatic Adenocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer |
Gilead Sciences |
2012-03 | PHASE1 |
| NCT02001896 | UNKNOWN | Non-Small Cell Lung Cancer |
Xinjiang Medical University |
2013-12 | PHASE3 |
| NCT01126749 | TERMINATED | Bladder Cancer |
Eisai Inc. |
2010-04-16 | PHASE1; PHASE2 |
| NCT01007552 | COMPLETED | Cholangiocarcinoma |
Roswell Park Cancer Institute |
2009-12 | PHASE2 |
| NCT01812018 | UNKNOWN | Soft Tissue Sarcoma |
Peng Yuan |
2012-11 | PHASE2 |
| NCT02046304 | COMPLETED | Sarcoma |
M.D. Anderson Cancer Center |
2001-12 | PHASE1 |
| NCT01815242 | COMPLETED | Breast Cancer |
Women's Cancer Study Group GmbH |
2013-06 | PHASE2 |
| NCT01797913 | COMPLETED | THE Efficacy and Safety of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer |
Fudan University |
2008-08 | PHASE2 |
| NCT01851174 | TERMINATED | Pancreatic Carcinoma Non-resectable; Stage IV Pancreatic Cancer |
Western Regional Medical Center |
2013-02 | PHASE2 |
| NCT01781988 | COMPLETED | Lung Cancer; Carboplatin Adverse Reaction |
Guangzhou Medical University |
2009-06 | PHASE2 |
| NCT00690872 | UNKNOWN | Head and Neck Cancer |
National Cancer Centre, Singapore |
2008-07 | PHASE2 |
| NCT01426633 | COMPLETED | Leiomyosarcoma; Liposarcoma |
Heidelberg University |
2011-11 | PHASE1 |
| NCT01050426 | TERMINATED | Pancreatic Cancer |
Royal Marsden NHS Foundation Trust |
2009-03 | PHASE2 |
| NCT02496832 | WITHDRAWN | Pancreatic Adenocarcinoma; Advanced Disease; Metastatic Disease |
University Health Network, Toronto |
2014-11 | |
| NCT01196559 | COMPLETED | Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer |
The Catholic University of Korea |
2011-01 | PHASE2 |
| NCT01754623 | TERMINATED | Pancreatic Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2013-02 | PHASE2 |
| NCT00948935 | COMPLETED | Biliary Cancer; Cholangiocarcinoma |
Abramson Cancer Center at Penn Medicine |
2009-04 | PHASE2 |
| NCT01860040 | TERMINATED | Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer; Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer |
Western Regional Medical Center |
2013-04 | PHASE2 |
| NCT01483300 | UNKNOWN | Breast Cancer |
Harbin Medical University |
2011-11 | PHASE2 |
| NCT00949949 | COMPLETED | Cholangiocarcinoma of the Gallbladder; Localized Gallbladder Cancer; Unresectable Gallbladder Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
Mayo Clinic |
2009-09 | PHASE1 |
| NCT00733850 | COMPLETED | Pancreatic Cancer |
KangLaiTe USA |
2008-08 | PHASE2 |
| NCT01570582 | UNKNOWN | Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer |
Korean Gynecologic Oncology Group |
2010-03 | PHASE2 |
| NCT00648648 | COMPLETED | Solid Tumors |
Merck Sharp & Dohme LLC |
2008-02-25 | PHASE1 |
| NCT01663285 | TERMINATED | Urothelial Cancer; Bladder Cancer |
University of Michigan Rogel Cancer Center |
2012-09 | PHASE2 |
| NCT01167816 | TERMINATED | Pancreatic Cancer |
University of Oklahoma |
2010-07 | PHASE1 |
| NCT01505413 | COMPLETED | Pancreatic Cancer |
Soonchunhyang University Hospital |
2011-01 | PHASE2 |
| NCT01236716 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Chinese Society of Lung Cancer |
2010-11 | PHASE2 |
| NCT01447225 | COMPLETED | Solid Tumors |
Merrimack Pharmaceuticals |
2011-10 | PHASE1 |
| NCT02808091 | TERMINATED | Extranodal NK-T-CELL LYMPHOMA |
National Cancer Centre, Singapore |
2011-03 | PHASE2 |
| NCT01298401 | COMPLETED | Pancreatic Cancer |
Radiation Therapy Oncology Group |
2012-02 | PHASE1 |
| NCT01472198 | COMPLETED | Pancreatic Cancer |
Gilead Sciences |
2011-11 | PHASE2 |
| NCT01063192 | UNKNOWN | Locally Advanced Pancreatic Cancer |
National Health Research Institutes, Taiwan |
2009-11 | PHASE2 |
| NCT01324258 | COMPLETED | Solid Tumours |
GlaxoSmithKline |
2011-01-24 | PHASE1 |
| NCT00842712 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Merck KGaA, Darmstadt, Germany |
2009-02 | PHASE2 |
| NCT01929421 | COMPLETED | Advanced Colorectal Cancer |
Gachon University Gil Medical Center |
2009-12 | PHASE2 |
| NCT01352494 | UNKNOWN | Breast Cancer Stage II; Breast Cancer Stage III |
Korean Breast Cancer Study Group |
2011-05 | PHASE2 |
| NCT01641575 | TERMINATED | Solid Tumor; Non-small-cell Lung Cancer; Lung Cancer |
Clovis Oncology, Inc. |
2012-07 | PHASE1 |
| NCT01684449 | COMPLETED | Advanced Soft Tissue Sarcoma |
Grupo Espanol de Investigacion en Sarcomas |
2010-01 | PHASE1; PHASE2 |
| NCT01633645 | COMPLETED | Non Small Cell Lung Cancer; Metastatic |
University Hospital of Crete |
2009-06 | PHASE2 |
| NCT00438204 | TERMINATED | Lung Cancer |
Barbara Ann Karmanos Cancer Institute |
2006-05 | PHASE2 |
| NCT01096745 | TERMINATED | Metastatic Biliary Tract Cancer; Locally Advanced Biliary Tract Cancer |
Gyeongsang National University Hospital |
2010-07 | PHASE2 |
| NCT00655785 | COMPLETED | Pancreatic Cancer |
Fukushima Medical University |
2007-09 | PHASE1; PHASE2 |
| NCT00639925 | UNKNOWN | Pancreatic Cancer |
Fukushima Medical University |
2007-03 | PHASE1 |
| NCT01251640 | COMPLETED | Pancreatic Neoplasms |
Bayer |
2011-01-01 | PHASE1; PHASE2 |
| NCT00634725 | COMPLETED | Pancreatic Cancer |
GERCOR - Multidisciplinary Oncology Cooperative Group |
2008-02 | PHASE3 |
| NCT01282333 | TERMINATED | Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Stage III Bladder Cancer; Stage III Pancreatic Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Bladder Cancer; Stage IV Non-small Cell Lung Cancer; Stage IV Pancreatic Cancer; Transitional Cell Carcinoma of the Bladder; Unresectable Extrahepatic Bile Duct Cancer; Unresectable Gallbladder Cancer |
National Cancer Institute (NCI) |
2011-01 | PHASE1 |
| NCT00810719 | COMPLETED | Pancreatic Cancer |
University of California, Davis |
2009-04 | PHASE2 |
| NCT01064622 | COMPLETED | Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7 |
National Cancer Institute (NCI) |
2009-09-03 | PHASE2 |
| NCT00169195 | COMPLETED | Diffuse Large Cell Lymphoma |
Lymphoma Study Association |
2003-04 | PHASE2 |
| NCT00082862 | UNKNOWN | Pancreatic Cancer |
The University of Texas Health Science Center, Houston |
2002-07 | PHASE2 |
| NCT00500422 | COMPLETED | Solid Tumors |
M.D. Anderson Cancer Center |
2005-01 | PHASE1 |
| NCT01161186 | COMPLETED | Pancreatic Neoplasms; Pancreatic Cancer; Adenocarcinoma |
University of California, San Francisco |
2010-07 | PHASE1 |
| NCT01020006 | COMPLETED | Pancreatic Cancer; Ductal Adrenocarcinoma; Exocrine Pancreatic Cancer |
Pharmacyclics LLC. |
2009-11 | PHASE2 |
| NCT00109928 | COMPLETED | Lymphoma |
SWOG Cancer Research Network |
2005-09 | PHASE2 |
| NCT01130142 | COMPLETED | Metastatic Pancreatic Cancer |
Infinity Pharmaceuticals, Inc. |
2010-04 | PHASE1; PHASE2 |
| NCT01151761 | TERMINATED | Cholangiocarcinoma; Hepatobiliary Neoplasm; Liver Cancer; Bile Duct Cancer; Cancer of Gallbladder |
Stanford University |
2011-01 | PHASE2 |
| NCT00867126 | TERMINATED | Pancreatic Cancer |
University of Texas Southwestern Medical Center |
2009-03-02 | EARLY_PHASE1 |
| NCT00789633 | COMPLETED | Pancreatic Cancer |
AB Science |
2008-11-25 | PHASE3 |
| NCT00771810 | COMPLETED | Thrombocytopenia; Neutropenia; Lymphopenia; Anemia |
Tarix Pharmaceuticals |
2008-10 | PHASE2 |
| NCT00846027 | COMPLETED | Breast Cancer |
Hoffmann-La Roche |
2009-01 | PHASE2 |
| NCT00588666 | COMPLETED | Myeloproliferative Disorder; Urothelial Carcinoma; Cancer |
Memorial Sloan Kettering Cancer Center |
2006-05 | PHASE2 |
| NCT00714948 | TERMINATED | Bladder Cancer; URINARY BLADDER |
Memorial Sloan Kettering Cancer Center |
2008-07 | PHASE2 |
| NCT01218880 | UNKNOWN | Pancreatic Cancer |
Beijing Protgen Biotechnology Development Co., Ltd. |
2010-06 | PHASE1 |
| NCT00601627 | COMPLETED | Pancreatic Cancer |
Alliance for Clinical Trials in Oncology |
2009-06 | PHASE2 |
| NCT00954005 | TERMINATED | Indolent Lymphoma |
German Low Grade Lymphoma Study Group |
2003-01 | PHASE1; PHASE2 |
| NCT00509665 | COMPLETED | Head and Neck Cancer |
Medical University of South Carolina |
2005-06 | PHASE2 |
| NCT00477035 | COMPLETED | Leukemia; Multiple Myeloma |
Sally Arai |
2006-05 | PHASE1 |
| NCT00938652 | COMPLETED | Breast Cancer |
Sanofi |
2009-07 | PHASE3 |
| NCT00696696 | COMPLETED | Pancreatic Cancer |
NYU Langone Health |
2007-09 | PHASE2 |
| NCT00660725 | COMPLETED | Advanced Incurable Solid Malignancy |
Leonard Appleman |
2009-02 | PHASE1 |
| NCT02146703 | COMPLETED | Biliary Tract Neoplasm |
Hallym University Medical Center |
2005-08 | PHASE2 |
| NCT00673179 | TERMINATED | Osteosarcoma |
M.D. Anderson Cancer Center |
2008-05 | |
| NCT00114244 | COMPLETED | Stage IV Pancreatic Cancer |
National Cancer Institute (NCI) |
2004-12 | PHASE2 |
| NCT00783172 | TERMINATED | Pancreatic Cancer |
Milton S. Hershey Medical Center |
2009-01 | PHASE1 |
| NCT00662129 | COMPLETED | Breast Cancer |
Alliance for Clinical Trials in Oncology |
2008-11 | PHASE2 |
| NCT00661830 | COMPLETED | Adenocarcinoma |
PD Dr Markus Möhler |
2008-05 | PHASE2 |
| NCT00778128 | COMPLETED | Solid Tumors |
Clavis Pharma |
2008-10 | PHASE1 |
| NCT00449033 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Bayer |
2007-02 | PHASE3 |
| NCT00837031 | COMPLETED | Metastatic Pancreatic Cancer |
SCRI Development Innovations, LLC |
2009-02 | PHASE2 |
| NCT00833859 | TERMINATED | Pancreatic Neoplasms |
H. Lee Moffitt Cancer Center and Research Institute |
2009-03 | PHASE2 |
| NCT00456261 | COMPLETED | Lung Cancer |
SCRI Development Innovations, LLC |
2007-03 | PHASE2 |
| NCT00832689 | COMPLETED | Biliary Tract Cancer |
Yonsei University |
2008-06 | PHASE2 |
| NCT00073983 | COMPLETED | Sarcoma |
Sarcoma Alliance for Research through Collaboration |
2006-10 | PHASE2 |
| NCT00625352 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Ulsan University Hospital |
2008-02 | PHASE2 |
| NCT00493441 | TERMINATED | Pancreatic Cancer |
Vertex Pharmaceuticals Incorporated |
2007-06 | PHASE2 |
| NCT00570713 | COMPLETED | Pancreatic Cancer |
Morphotek |
2007-12 | PHASE2 |
| NCT00436280 | COMPLETED | Lymphoma, Large Cell, Diffuse |
Eli Lilly and Company |
2007-02 | PHASE2 |
| NCT00201760 | COMPLETED | Breast Cancer |
Kari Kendra |
2005-02-25 | PHASE2 |
| NCT00452881 | UNKNOWN | Lung Cancer |
National Cancer Center, Korea |
2006-05 | PHASE2 |
| NCT00844688 | UNKNOWN | Hepatocellular Carcinoma |
Combined Military Hospital, Pakistan |
2008-09 | PHASE2 |
| NCT00906061 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Hospital Arnau de Vilanova |
2007-10 | PHASE2 |
| NCT00327327 | COMPLETED | Pancreatic Adenocarcinoma |
AmpliMed Corporation |
2004-02 | PHASE1 |
| NCT00593008 | TERMINATED | Pancreatic Adenocarcinoma |
Massachusetts General Hospital |
2007-10 | PHASE1 |
| NCT00215930 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
H. Lee Moffitt Cancer Center and Research Institute |
2004-02 | PHASE2 |
| NCT00101283 | COMPLETED | Mesothelioma |
Eastern Cooperative Oncology Group |
2006-02-23 | PHASE2 |
| NCT00860015 | COMPLETED | Sarcoma, Soft Tissue |
Columbia University |
2005-08 | PHASE2 |
| NCT00960284 | COMPLETED | Pancreatic Cancer |
IRCCS San Raffaele |
2003-06 | PHASE2; PHASE3 |
| NCT00354549 | COMPLETED | Lung Cancer |
Swiss Cancer Institute |
2006-01 | PHASE2 |
| NCT00337259 | TERMINATED | Non-Hodgkin's Lymphoma; Marginal Zone Lymphoma |
Asan Medical Center |
2006-06 | PHASE2 |
| NCT00859469 | COMPLETED | Mesothelioma |
Columbia University |
2004-04 | PHASE2 |
| NCT00744640 | COMPLETED | Locally Advanced Pancreatic Cancer; Metastatic Pancreatic Cancer |
University Hospital, Basel, Switzerland |
2005-10 | PHASE1; PHASE2 |
| NCT00470249 | TERMINATED | Breast Cancer |
University of Southampton |
2006-07-15 | PHASE2 |
| NCT00191152 | COMPLETED | Breast Cancer; Breast Neoplasms; Cancer of the Breast |
Eli Lilly and Company |
2002-02 | PHASE3 |
| NCT00191139 | COMPLETED | Non-small Cell Lung Cancer |
Eli Lilly and Company |
2003-03 | PHASE2 |
| NCT00191451 | COMPLETED | Breast Cancer |
Eli Lilly and Company |
2004-04 | PHASE2 |
| NCT02004093 | COMPLETED | Ovarian Cancer |
Hoffmann-La Roche |
2005-12 | PHASE2 |
| NCT00100815 | COMPLETED | Pancreatic Cancer |
Roswell Park Cancer Institute |
2004-08 | PHASE2 |
| NCT00394147 | TERMINATED | Head and Neck Cancer |
Fox Chase Cancer Center |
2006-10 | PHASE2 |
| NCT00447122 | TERMINATED | Metastatic Pancreatic Cancer |
Brown University |
2007-03 | PHASE1 |
| NCT00047307 | COMPLETED | Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer |
National Cancer Institute (NCI) |
2002-08 | PHASE1 |
| NCT00401570 | COMPLETED | Pancreatic Cancer |
AbbVie (prior sponsor, Abbott) |
2005-03 | PHASE2 |
| NCT00254904 | TERMINATED | Carcinoma, Non-Small-Cell Lung |
Pfizer |
2005-11 | PHASE3 |
| NCT00184093 | COMPLETED | Uterine Cervical Cancer |
University of Southern California |
1999-06 | PHASE1; PHASE2 |
| NCT00610740 | COMPLETED | Cervical Cancer; Endometrial Cancer; Ovarian Cancer |
Masonic Cancer Center, University of Minnesota |
2006-07 | PHASE2 |
| NCT00372944 | COMPLETED | Pancreatic Cancer |
AstraZeneca |
2006-08 | PHASE2 |
| NCT00496301 | COMPLETED | Carcinoma, Renal Cell |
Spanish Oncology Genito-Urinary Group |
2006-11 | PHASE2 |
| NCT00636311 | COMPLETED | Hodgkin Disease |
Istituto Clinico Humanitas |
2008-02 | PHASE2 |
| NCT00191269 | COMPLETED | Metastatic Breast Cancer |
Eli Lilly and Company |
2005-06 | PHASE2 |
| NCT00163761 | COMPLETED | Non-Hodgkin's Lymphoma; Hodgkin's Disease |
Bayside Health |
2002-12 | PHASE2 |
| NCT00330746 | COMPLETED | Advanced Non-Small Cell Lung Cancer |
National Cancer Institute, Naples |
2005-11 | PHASE2 |
| NCT00063570 | COMPLETED | Breast Cancer; Breast Neoplasms |
Eli Lilly and Company |
2003-07 | PHASE2 |
| NCT00401609 | COMPLETED | Small Cell Lung Cancer |
National Cancer Institute, Naples |
2000-11 | PHASE1; PHASE2 |
| NCT00288925 | COMPLETED | Pancreatic Cancer |
Zeria Pharmaceutical |
2005-09 | PHASE1; PHASE2 |
| NCT00305786 | COMPLETED | Lung Cancer |
University of Miami |
2005-08 | PHASE2 |
| NCT00052689 | COMPLETED | Duct Cell Adenocarcinoma of the Pancreas; Stage IV Pancreatic Cancer |
National Cancer Institute (NCI) |
2002-12 | PHASE2 |
| NCT00202800 | COMPLETED | Pancreatic Cancer |
Corewell Health West |
2002-03 | PHASE2 |
| NCT00336648 | COMPLETED | Pancreatic Neoplasms |
M.D. Anderson Cancer Center |
2006-06 | PHASE2 |
| NCT00307255 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
UNC Lineberger Comprehensive Cancer Center |
2006-08 | PHASE1 |
| NCT00258739 | COMPLETED | Lung Neoplasms |
Sanofi |
2001-10 | PHASE2 |
| NCT00397787 | COMPLETED | Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer |
National Cancer Institute (NCI) |
2006-11 | PHASE2 |
| NCT00075751 | COMPLETED | Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2004-01 | PHASE2 |
| NCT00101907 | TERMINATED | Lung Cancer; Pancreatic Cancer; Esophageal Cancer |
Amgen |
2004-12 | PHASE1 |
| NCT00217282 | COMPLETED | Non-Small Cell Lung Cancer |
Mt. Sinai Medical Center, Miami |
2004-06 | PHASE2 |
| NCT01172470 | COMPLETED | Head and Neck Cancer |
University of Chicago |
2005-06 | PHASE2 |
| NCT00652054 | COMPLETED | Metastatic Pancreatic Cancer |
Taiho Oncology, Inc. |
2005-06 | PHASE2 |
| NCT00660140 | COMPLETED | Cholangiocarcinoma; Gallbladder Cancer |
Washington University School of Medicine |
2002-03 | PHASE2 |
| NCT00401492 | COMPLETED | Non Small Cell Lung Cancer |
National Cancer Institute, Naples |
2002-06 | PHASE2 |
| NCT00026104 | COMPLETED | Adenocarcinoma of the Pancreas; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer |
National Cancer Institute (NCI) |
2001-11 | PHASE2 |
| NCT00112528 | COMPLETED | Pancreatic Cancer |
Alliance for Clinical Trials in Oncology |
2005-06 | PHASE2 |
| NCT00055835 | COMPLETED | Bladder Cancer; Urethral Cancer |
SWOG Cancer Research Network |
2002-11 | PHASE2 |
| NCT00532285 | TERMINATED | Breast Cancer |
National Cancer Center, Korea |
2005-09 | PHASE2 |
| NCT00136175 | COMPLETED | Bladder Cancer |
University of Michigan Rogel Cancer Center |
1999-11 | PHASE2 |
| NCT00154739 | COMPLETED | Non-Small Cell Lung Cancer |
National Taiwan University Hospital |
1998-10 | PHASE2 |
| NCT00193362 | COMPLETED | Lung Cancer |
SCRI Development Innovations, LLC |
2004-06 | PHASE3 |
| NCT00077350 | COMPLETED | Recurrent Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2004-07 | PHASE2 |
| NCT00003727 | COMPLETED | Leukemia |
University of Maryland, Baltimore |
1999-03 | PHASE2 |
| NCT00217698 | COMPLETED | Lung Cancer |
Swiss Cancer Institute |
2003-11 | PHASE2 |
| NCT00003851 | TERMINATED | Malnutrition; Pancreatic Cancer |
Columbia University |
1999-03 | |
| NCT00052338 | COMPLETED | Malignant Pleural Effusion; Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2002-09 | PHASE1 |
| NCT00033241 | COMPLETED | Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
OSI Pharmaceuticals |
2001-07-23 | PHASE1 |
| NCT00176813 | COMPLETED | Pancreatic Cancer |
University of Michigan Rogel Cancer Center |
2003-03 | PHASE2 |
| NCT00005991 | COMPLETED | Breast Cancer |
M.D. Anderson Cancer Center |
1997-08-25 | PHASE2 |
| NCT00020774 | WITHDRAWN | Liver Cancer |
Jonsson Comprehensive Cancer Center |
1998-10 | PHASE2 |
| NCT00003202 | COMPLETED | Lung Cancer |
Wake Forest University Health Sciences |
1998-01 | PHASE1; PHASE2 |
| NCT00003426 | COMPLETED | Pancreatic Cancer |
Memorial Sloan Kettering Cancer Center |
1998-04 | PHASE1 |
| NCT00003587 | COMPLETED | Lung Cancer |
SWOG Cancer Research Network |
1998-10 | PHASE2 |
| NCT00003358 | COMPLETED | Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer |
Memorial Sloan Kettering Cancer Center |
1998-01 | PHASE1 |
| NCT00003589 | COMPLETED | Lung Cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
1998-08 | PHASE3 |
| NCT00003378 | TERMINATED | Ovarian Cancer; Primary Peritoneal Cavity Cancer |
Gynecologic Oncology Group |
1998-08 | PHASE1 |
| NCT00168870 | UNKNOWN | Ocular Melanoma |
Charite University, Berlin, Germany |
2003-02 | PHASE2 |
| NCT00352859 | TERMINATED | Carcinoma, Renal Cell |
Bayer |
2006-08 | PHASE4 |
| NCT00061451 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Eli Lilly and Company |
2002-12 | PHASE2 |
| NCT00561054 | UNKNOWN | Carcinoma, Non-Small-Cell Lung |
Grupo Portugues de Estudo do Cancro do Pulmao |
2007-03 | PHASE2 |
| NCT00491114 | COMPLETED | Bladder Neoplasms |
Eli Lilly and Company |
2003-07 | PHASE2 |
| NCT00275119 | UNKNOWN | Pancreatic Cancer |
GERCOR - Multidisciplinary Oncology Cooperative Group |
2003-11 | PHASE2 |
| NCT00261092 | COMPLETED | Pancreatic Neoplasms |
Sanofi |
2005-10 | PHASE2 |
| NCT00192712 | COMPLETED | Pancreatic Cancer |
Rambam Health Care Campus |
2002-11 | PHASE2; PHASE3 |
| NCT00115635 | COMPLETED | Prostate Cancer |
Herlev Hospital |
2005-03 | PHASE1; PHASE2 |
| NCT00736814 | UNKNOWN | Lung Cancer |
Yonsei University |
2008-06 | PHASE2 |
| NCT00020345 | COMPLETED | Stage IVA Pancreatic Cancer; Stage III Pancreatic Cancer; Adenocarcinoma of the Pancreas |
National Institutes of Health Clinical Center (CC) |
2000-09 | PHASE2 |
| NCT00563160 | UNKNOWN | Lung Neoplasms |
Hospital Authority, Hong Kong |
2005-05 | PHASE2 |
| NCT00003182 | UNKNOWN | Head and Neck Cancer |
Hope Cancer Institute, Inc. |
1997-03 | PHASE1; PHASE2 |
| NCT00490880 | COMPLETED | Bladder Cancer |
Eli Lilly and Company |
2003-11 | PHASE2 |
| NCT00055432 | TERMINATED | Ovarian Cancer; Peritoneal Cancer |
Eli Lilly and Company |
PHASE2 | |
| NCT00004100 | UNKNOWN | Lung Cancer |
Istituto Nazionale per lo Studio e la Cura dei Tumori |
1998-11 | PHASE3 |
| NCT00271271 | COMPLETED | Non Small Cell Lung Cancer |
Sanofi |
2003-06 | PHASE2 |
| NCT00191763 | COMPLETED | Carcinoma, Non-Small-Cell-Lung Cancer |
Eli Lilly and Company |
2002-11 | PHASE2 |
| NCT00003780 | UNKNOWN | Pancreatic Cancer |
Meyer Pharmaceuticals |
1998-12 | PHASE2 |
| NCT00201305 | COMPLETED | Biliary Tract Disease |
National Health Research Institutes, Taiwan |
2002-07 | PHASE2 |
| NCT00003447 | UNKNOWN | Lung Cancer |
Istituto Nazionale per lo Studio e la Cura dei Tumori |
1998-07 | PHASE3 |
| NCT00019513 | COMPLETED | Colorectal Cancer; Esophageal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer; Lung Cancer; Lymphoma; Pancreatic Cancer; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
National Institutes of Health Clinical Center (CC) |
1998-08 | PHASE1 |
| NCT00398697 | COMPLETED | Neoplasms |
AEterna Zentaris |
2004-08 | PHASE1 |
| NCT00005926 | COMPLETED | Pancreatic Cancer; Pancreatic Neoplasm |
National Cancer Institute (NCI) |
2000-06 | PHASE2 |
| NCT00061477 | COMPLETED | Mesothelioma |
Eli Lilly and Company |
2002-12 | PHASE2 |
| NCT00191347 | COMPLETED | Breast Cancer |
Eli Lilly and Company |
2004-10 | PHASE2 |
| NCT00139971 | UNKNOWN | Lung Cancer |
West Japan Thoracic Oncology Group |
2001-12 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2026-04-14)
Check the
Gemcitabine Hydrochloride
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Gemcitabine Hydrochloride Mechanism of Action: Ribonucleotide Reductase Inhibition in Pancreatic Tumor Cell Research
- Gemcitabine Hydrochloride: Selectivity & Specificity
- Gemcitabine Hydrochloride Working Concentration | Cell Culture | Treatment
- Gemcitabine Hydrochloride Solubility in DMSO
- Gemcitabine Hydrochloride Stock Solution
- Gemcitabine Hydrochloride Storage
- Gemcitabine Hydrochloride Stability
- Gemcitabine Hydrochloride Combination Database
- Gemcitabine Hydrochloride Molecular Weight
- Gemcitabine Hydrochloride SMILES
- Gemcitabine Hydrochloride CAS Number
- Gemcitabine Hydrochloride Chemical Structure (2D and 3D)
- Gemcitabine Hydrochloride IC50 for Cell-based and Cell-free Assays
- Gemcitabine Hydrochloride Sigma (G6423)? Try a better option.
- Gemcitabine Hydrochloride MedChemExpress (HY-B0003)? Try a better option.
- Gemcitabine Hydrochloride Cayman (9003096)? Try a better option.
- Gemcitabine Hydrochloride APExBIO (A1402)? Try a better option.
- Gemcitabine Hydrochloride Tocris (3259)? Try a better option.
- Gemcitabine Hydrochloride SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.